Clinical Research Directory
Browse clinical research sites, groups, and studies.
A Study of Novel Agents or Combinations as Perioperative Treatment in Participants With Locally Advanced Resectable Gastroesophageal Adenocarcinoma
Sponsor: AstraZeneca
Summary
GEMINI-PeriOp GC study will assess the safety, tolerability, pharmacokinetics (PK) and preliminary anti-tumor activity of novel agents or novel combinations as perioperative treatment in participants with locally advanced resectable gastric, gastroesophageal junction (GEJ), or esophageal adenocarcinoma who have not received previous treatment for the disease.
Official title: A Master Protocol of an Open-Label, Multi-Drug, Multi-Center, Phase II Platform Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Anti-tumor Activity of Novel Agents or Combinations as Perioperative Treatment in Participants With Locally Advanced Resectable Gastroesophageal Adenocarcinoma (GEMINI-PeriOp GC)
Key Details
Gender
All
Age Range
18 Years - Any
Study Type
INTERVENTIONAL
Enrollment
100
Start Date
2025-07-17
Completion Date
2028-09-06
Last Updated
2026-03-10
Healthy Volunteers
No
Conditions
Interventions
AZD0901
AZD0901 will be administered as an IV infusion.
Rilvegostomig
Rilvegostomig will be administered as an IV infusion.
Trastuzumab Deruxtecan (T-DXd)
T-DXd will be administered as an IV infusion.
Capecitabine
Capecitabine (Fluoropyrimidine) will be administered orally as chemotherapy standard of care.
5-Fluorouracil (5-FU)
5-FU (Fluoropyrimidine) will be administered as an IV infusion as chemotherapy standard of care.
FLOT Chemotherapy
FLOT (5-FU, leucovorin, oxaliplatin, and docetaxel) Chemotherapy will be administered as an IV infusion.
Locations (70)
Research Site
Newark, Delaware, United States
Research Site
Washington D.C., District of Columbia, United States
Research Site
Fairway, Kansas, United States
Research Site
North Shores, Michigan, United States
Research Site
New York, New York, United States
Research Site
New York, New York, United States
Research Site
Pittsburgh, Pennsylvania, United States
Research Site
Toronto, Ontario, Canada
Research Site
Montreal, Quebec, Canada
Research Site
Montreal, Quebec, Canada
Research Site
Beijing, China
Research Site
Changchun, China
Research Site
Changzhi, China
Research Site
Chengdu, China
Research Site
Chengdu, China
Research Site
Fuzhou, China
Research Site
Hangzhou, China
Research Site
Hangzhou, China
Research Site
Kunming, China
Research Site
Qingdao, China
Research Site
Shanghai, China
Research Site
Shijiazhuang, China
Research Site
Tbilisi, Georgia
Research Site
Tbilisi, Georgia
Research Site
Tbilisi, Georgia
Research Site
Tbilisi, Georgia
Research Site
Florence, Italy
Research Site
Milan, Italy
Research Site
Milan, Italy
Research Site
Milan, Italy
Research Site
Modena, Italy
Research Site
Pisa, Italy
Research Site
Rozzano, Italy
Research Site
Udine, Italy
Research Site
Vicenza, Italy
Research Site
Chūōku, Japan
Research Site
Fukuoka, Japan
Research Site
Hidaka-shi, Japan
Research Site
Kashiwa, Japan
Research Site
Kitaadachi-gun, Japan
Research Site
Kōtoku, Japan
Research Site
Nagoya, Japan
Research Site
Osaka, Japan
Research Site
Osaka, Japan
Research Site
Suita-shi, Japan
Research Site
Yokohama, Japan
Research Site
Bialystok, Poland
Research Site
Warsaw, Poland
Research Site
Barcelona, Spain
Research Site
Barcelona, Spain
Research Site
Elche, Spain
Research Site
Madrid, Spain
Research Site
Málaga, Spain
Research Site
Ourense, Spain
Research Site
Oviedo, Spain
Research Site
Santander, Spain
Research Site
Valencia, Spain
Research Site
Kaohsiung City, Taiwan
Research Site
Tainan, Taiwan
Research Site
Taipei, Taiwan
Research Site
Taoyuan District, Taiwan
Research Site
Adapazarı, Turkey (Türkiye)
Research Site
Erzurum, Turkey (Türkiye)
Research Site
Fatih-Istanbul, Turkey (Türkiye)
Research Site
Istanbul, Turkey (Türkiye)
Research Site
Bristol, United Kingdom
Research Site
Dundee, United Kingdom
Research Site
Headington, United Kingdom
Research Site
London, United Kingdom
Research Site
Norwich, United Kingdom